6β-OHFC/FC在白血病患儿不同化疗阶段的区别与意义  

Difference and Implication of 6β-OHFC/FC Ratio at Different Phases of Chemotherapy for Leukemia Children

作　　者：唐跃年[1] 张健[1] 袁晓军[2] 顾龙君[2] 

机构地区：[1]上海交通大学医学院附属新华医院药剂科,上海市200092 [2]上海交通大学医学院附属新华医院上海儿童医学中心,上海市200092

出　　处：《中国药房》2007年第11期832-834,共3页China Pharmacy

基　　金：上海市卫生局科研课题(044057)

摘　　要：目的:探讨6β-羟基氢化可的松与氢化可的松比值(6β-OHFC/FC)在白血病患儿不同化疗阶段的区别及意义。方法:采用尿样法,以HPLC法测定并计算6β-OHFC/FC。结果:不同化疗阶段的白血病患儿,6β-OHFC/FC有显著性差异。结论:6β-OHFC/FC对白血病患儿的治疗、预后评估及其危险度分级有一定的参考价值。OBJECTIVE：To study the difference and implication of 613-OHFC/FC ratio at different phases of chemotherapy for leukemia children.METHODS： Urine samples were used for determination of 6β-OHFC/ FC by HPLC.RESULTS： 6β- OHFC/FC ratio had marked differences at different phases of treatment for leukemia children.CONCLUSIONS： 6β-OHFC/FC ratio is of certain value in providing reference for treatment of children with leukemia,prognostic evaluation and risk classification.

关 键 词：白血病 6β—OHFC/FC 化疗 

分 类 号：R969.1[医药卫生—药理学]